Is YD Bio Limited Ordinary Shares (YDES) Overvalued or Undervalued?Intrinsic Value Overview
YD Bio Limited Ordinary Shares (YDES)
YD Bio Limited Ordinary Shares (YDES) intrinsic value summary: current price $8.45, fair value N/A, N/A implied move via DCF and relative valuation.
Method Breakdown
Base blend: 60% DCF + 40% RelativeCompany Quality
Below average — notable weaknesses in key areas
Wall St Estimates
Shareholder Returns
Total Return vs S&P 500
Fundamental Analysis
Profitability & Financial HealthProfitability
Returns & MarginsSolvency
Financial HealthGrowth & Margins
Quarterly Trends · 5-Year Window · Hover for detailPiotroski F-Score
Fundamental QualityMonte Carlo Distribution & Risk
10,000 SimulationsModel Observation History
Quantitative Track RecordMonthly model snapshots showing quantitative assessments. High Conviction = model detected notable undervaluation vs peers. Return columns show actual price changes following each observation date for reference purposes only.
| Date | Assessment | Score | Price | 30d | 90d |
|---|---|---|---|---|---|
| Jan 11, 26Latest | Neutral | 0.18 | $12.34 | — | — |
| Dec 12, 25 | Neutral | 0.18 | $12.40 | -0.5% | — |
| Nov 12, 25 | Neutral | 0.18 | $8.84 | +40.3% | +28.2% |
| Oct 13, 25 | Neutral | 0.18 | $18.46 | -52.1% | -33.1% |
| Sep 13, 25 | Neutral | 0.18 | $23.11 | -20.1% | -46.3% |
Peer Valuation Comparison
Biotechnology CohortAnnual Returns vs SPY
Total Return (Price + Dividends)| Year | Stock Return | SPY Return | Alpha |
|---|---|---|---|
| 2026YTDWorst | -28.5% | +0.4% | -28.9% |
| 2025Best | +1.2% | +16.6% | -15.4% |
Frequently Asked Questions
ValuationIs YDES a good stock to buy right now?
Based on our multi-model analysis of YD Bio Limited Ordinary Shares (YDES) at $8.45: Fundamental quality score: 35/100 (below average). This is a quantitative summary combining DCF intrinsic value, peer-based relative valuation, quality scoring, and analyst consensus — not a buy/sell recommendation. Always consult a qualified financial advisor before investing.
ValuationWhat is YD Bio Limited Ordinary Shares's fair value?
Fair value data is not yet available for YDES.
QualityIs YDES financially healthy?
YD Bio Limited Ordinary Shares's financial health as measured by our composite scoring: Overall quality score: 35/100. Piotroski F-Score: 3/9 (weak fundamentals). Altman Z-Score: 100.0 (safe zone — low bankruptcy risk). Return on invested capital: -63.3%. Cash conversion (OCF/NI): 1.30x (earnings are cash-backed). The quality score blends profitability (ROIC, ROE, margins), solvency (leverage, coverage, Z-Score), and growth trajectory into a single 0–100 framework updated end-of-day.
PerformanceHow has YDES performed compared to the S&P 500?
YD Bio Limited Ordinary Shares's performance profile: 1-year total return: -29.8%. 1-year alpha vs S&P 500: -46.5% (underperforming the benchmark). 5-year CAGR: -6.8%. Maximum drawdown (1Y): -65.3%. Relative Strength rating: 19/99 (weak momentum). Beta: 1.64 (more volatile than the market). Total returns include reinvested dividends. Alpha is calculated against the S&P 500 Total Return Index over matching periods.
IncomeDoes YDES pay dividends?
YD Bio Limited Ordinary Shares does not currently pay a dividend or conduct significant share buybacks. The company is retaining capital for reinvestment.
EstimatesWhat do Wall Street analysts say about YDES?
No analyst coverage data available for YDES.
RiskWhat are the key risks of investing in YDES?
Key risks identified for YD Bio Limited Ordinary Shares: Drawdown risk: The stock experienced a -65.3% max drawdown in the past year. Volatility risk: Beta of 1.64 indicates significantly higher volatility than the broad market. Note: This model does not capture regulatory changes, management decisions, competitive disruption, or geopolitical events. Macro and qualitative risks remain material and should be assessed independently.
LegalDoes this dashboard provide investment advice?
No. This overview dashboard aggregates data from our DCF intrinsic value model, relative peer multiples model, proprietary estimates engine, and third-party analyst consensus feeds. It is strictly for educational and informational purposes. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, quality scores, and signals are automated quantitative computations and should not be construed as investment recommendations. Consult a qualified, licensed financial advisor before making any investment decisions. Past model performance does not guarantee future results.